Most Read

Bristol Myers Squibb has signed a license, development, and commercialisation agreement with clinical-stage biopharmaceutical firm Immatics for the latter’s TCR Bispecific candidate for solid tumours, IMA401. Under the

Novo Nordisk has announced plans to make more than $2.58bn (DKK17bn) investment to expand its manufacturing facilities in Kalundborg, Denmark. The company plans to construct three new manufacturing

The European Commission (EC) has approved Pfizer’s Cibinqo (abrocitinib) to treat moderate-to-severe atopic dermatitis (AD) adult patients. The 100mg and 200mg doses of the oral small molecule drug

AbbVie’s subsidiary Allergan has announced the availability of FDA-approved eye drop, VUITY (pilocarpine HCl ophthalmic solution) 1.25%, by prescription in pharmacies across the US. VUITY is a once-a-day

Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries. Trastuzumab (HD201),

By working with both Roche and Genentech’s R&D units, Recursion will tap technology-enabled drug discovery through its Operating System (OS) to more quickly identify novel targets and then

Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license

This deal is part of Merck’s commitment to make the drug available across the globe, following approval for use by regulatory bodies. Merck, in collaboration with Ridgeback Biotherapeutics,

The European Medicines Agency (EMA) has accepted to review Sanofi’s marketing authorization application (MAA) for olipudase alfa to treat acid sphingomyelinase deficiency (ASMD). An investigational enzyme replacement therapy,